全文获取类型
收费全文 | 4428篇 |
免费 | 216篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 47篇 |
妇产科学 | 38篇 |
基础医学 | 603篇 |
口腔科学 | 132篇 |
临床医学 | 263篇 |
内科学 | 1095篇 |
皮肤病学 | 35篇 |
神经病学 | 383篇 |
特种医学 | 162篇 |
外科学 | 679篇 |
综合类 | 12篇 |
预防医学 | 76篇 |
眼科学 | 350篇 |
药学 | 310篇 |
中国医学 | 2篇 |
肿瘤学 | 460篇 |
出版年
2023年 | 25篇 |
2022年 | 16篇 |
2021年 | 58篇 |
2020年 | 58篇 |
2019年 | 75篇 |
2018年 | 92篇 |
2017年 | 74篇 |
2016年 | 77篇 |
2015年 | 79篇 |
2014年 | 111篇 |
2013年 | 142篇 |
2012年 | 281篇 |
2011年 | 301篇 |
2010年 | 164篇 |
2009年 | 169篇 |
2008年 | 278篇 |
2007年 | 302篇 |
2006年 | 280篇 |
2005年 | 277篇 |
2004年 | 288篇 |
2003年 | 244篇 |
2002年 | 246篇 |
2001年 | 75篇 |
2000年 | 75篇 |
1999年 | 70篇 |
1998年 | 49篇 |
1997年 | 29篇 |
1996年 | 34篇 |
1995年 | 36篇 |
1994年 | 25篇 |
1993年 | 26篇 |
1992年 | 58篇 |
1991年 | 54篇 |
1990年 | 49篇 |
1989年 | 56篇 |
1988年 | 44篇 |
1987年 | 40篇 |
1986年 | 33篇 |
1985年 | 36篇 |
1984年 | 30篇 |
1983年 | 30篇 |
1979年 | 24篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1975年 | 14篇 |
1974年 | 12篇 |
1971年 | 17篇 |
1970年 | 14篇 |
1968年 | 12篇 |
1967年 | 13篇 |
排序方式: 共有4679条查询结果,搜索用时 31 毫秒
1.
Takehiko Mori Souichi Shiratori Junji Suzumiya Mineo Kurokawa Motohiro Shindo Uchida Naoyuki Takenaka Katsuto Toshihiro Miyamoto Satoshi Morishige Makoto Hirokawa Takahiro Fukuda Yoshiko Atsuta Ritsuro Suzuki 《Hematological oncology》2020,38(3):266-271
Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. 相似文献
2.
3.
4.
5.
6.
Byoung Chul Cho Busayamas Chewaskulyong Ki Hyeong Lee Arunee Dechaphunkul Virote Sriuranpong Fumio Imamura Naoyuki Nogami Takayasu Kurata Isamu Okamoto Caicun Zhou Ying Cheng Eun Kyung Cho Pei Jye Voon Jong-Seok Lee Helen Mann Matilde Saggese Thanyanan Reungwetwattana Suresh S. Ramalingam Yuichiro Ohe 《Journal of thoracic oncology》2019,14(1):99-106
Introduction
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI–sensitizing mutations.Methods
Eligible Asian patients (enrolled at Asian sites) who were at least 18 years of age (≥20 years in Japan) and had untreated EGFR-mutated advanced NSCLC were randomized 1:1 to receive osimertinib (80 mg, orally once daily) or an SoC EGFR TKI (gefitinib, 250 mg, or erlotinib, 150 mg, orally once daily). The primary end point was investigator-assessed progression-free survival (PFS). The key secondary end points were overall survival, objective response rate, central nervous system efficacy, and safety.Results
The median PFS was 16.5 versus 11.0 months for the osimertinib and SoC EGFR TKI groups, respectively (hazard ratio = 0.54, 95% confidence interval: 0.41–0.72, p < 0.0001). The overall survival data were immature (24% maturity). The objective response rates were 80% for osimertinib and 75% for an SoC EGFR TKI. The median central nervous system PFS was not calculable for the osimertinib group and was 13.8 months for the SoC EGFR TKI group (hazard ratio = 0.55, 95% confidence interval: 0.25–1.17, p = 0.118). Fewer adverse events of grade 3 or higher (40% versus 48%) and fewer adverse events leading to treatment discontinuation (15% versus 21%) were reported with osimertinib versus with an SoC EGFR TKI, respectively.Conclusion
In this Asian population, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over an SoC EGFR TKI, with a safety profile consistent with that for the overall FLAURA study population. 相似文献7.
Yoshiki Imamura Takahiro Shinozaki Akiko Okada‐Ogawa Noboru Noma Masahiro Shinoda Koichi Iwata Akihiko Wada Osamu Abe Kelun Wang Peter Svensson 《Journal of oral rehabilitation》2019,46(6):574-587
Burning mouth syndrome (BMS) is a chronic oro‐facial pain disorder of unknown cause. It is more common in peri‐ and post‐menopausal women, and sex hormone dysregulation is believed to be an important causative factor. Psychosocial events often trigger or exacerbate symptoms, and persons with BMS appear to be predisposed towards anxiety and depression. Atrophy of small nerve fibres in the tongue epithelium has been reported, and potential neuropathic mechanisms for BMS are now widely investigated. Historically, BMS was thought to comprise endocrinological, psychosocial and neuropathic components. Neuroprotective steroids and glial cell line–derived neurotrophic factor family ligands may have pivotal roles in the peripheral mechanisms associated with atrophy of small nerve fibres. Denervation of chorda tympani nerve fibres that innervate fungiform buds leads to alternative trigeminal innervation, which results in dysgeusia and burning pain when eating hot foods. With regard to the central mechanism of BMS, depletion of neuroprotective steroids alters the brain network–related mood and pain modulation. Peripheral mechanistic studies support the use of topical clonazepam and capsaicin for the management of BMS, and some evidence supports the use of cognitive behavioural therapy. Hormone replacement therapy may address the causes of BMS, although adverse effects prevent its use as a first‐line treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) may have important benefits, and well‐designed controlled studies are expected. Other treatment options to be investigated include brain stimulation and TSPO (translocator protein 18 kDa) ligands. 相似文献
8.
Taichi Goto Gojiro Nakagami Takeo Minematsu Sanai Tomida Masamichi Shinoda Koichi Iwata Hiromi Sanada 《Experimental dermatology》2019,28(9):1010-1016
Cutaneous wound pain causes physical and psychological stress for patients with wounds. Previous studies reported that stress induces hyperalgesia and deteriorates wound healing. However, the effect of the stress response such as in hypothalamic‐pituitary‐adrenal (HPA) axis on local wound area is unclear. We aimed to investigate the effects of a stress response on the mechanical withdrawal threshold in the local wound area and describe the identification of a wound pain exacerbation. We topically injected adrenocorticotropic hormone (ACTH) into the granulation tissue of full‐thickness cutaneous wound model rats on the fifth day postwounding and measured the mechanical withdrawal thresholds, cytochrome P450 2Bs levels and concentration of 5,6‐epoxyeicosatrienoic acid in wound exudate. We found that ACTH induced mechanical hypersensitivity at 4 and 6 hours after injection (P = .004 and .021, respectively), and increased gene expression of cytochrome P450 2B12 expression (P = .046). Concentration of 5,6‐EET in the wound exudate was moderately correlated with the mechanical withdrawal threshold (r = ?.630). Finally, the mechanical withdrawal threshold in the 5,6‐EET group was significantly lower than that in the control group at 2 hours after the injection (P = .015). We propose that 5,6‐EET is one of the most promising contributors to the wound pain exacerbation. These findings could guide clinical wound and pain management. 相似文献
9.
10.
High prevalence of toothache among Great East Japan Earthquake survivors living in temporary housing